The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Clinical challenges and future therapeutic approaches for neuronal ceroid lipofuscinosis
Open accessAbstract
Treatment of the neuronal ceroid lipofuscinoses, also known as Batten disease, is at the start of a new era because of diagnostic and therapeutic advances relevant to this group of inherited neurodegenerative and life-limiting disorders that affect children. Diagnosis has improved with the use of comprehensive DNA-based tests that simultaneously screen for many genes. The identification of disease-causing mutations in 13 genes provides a basis for understanding the molecular mechanisms underlying neuronal ceroid lipofuscinoses, and for the development of targeted therapies. These targeted therapies include enzyme replacement therapies, gene therapies targeting the brain and the eye, cell therapies, and pharmacological drugs that could modulate defective molecular pathways. Such therapeutic developments have the potential to enable earlier diagnosis and better targeted therapeutic management. The first approved treatment is an intracerebroventricularly administered enzyme for neuronal ceroid lipofuscinosis type 2 disease that delays symptom progression. Efforts are underway to make similar progress for other forms of the disorder.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Study of Intraventricular Cerliponase Alfa for CLN2 Disease
Schulz, A., Ajayi, T., Specchio, N., de Los Reyes, E., Gissen, P., Ballon, D., Dyke, J. P., Cahan, H., Slasor, P., Jacoby, D., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1712649 · Cited by 489
Self-citationStrikingly Different Clinicopathological Phenotypes Determined by Progranulin-Mutation Dosage
Smith, K. R., Damiano, J., Franceschetti, S., Carpenter, S., Canafoglia, L., Morbin, M., Rossi, G., Pareyson, D., Mole, S. E., Staropoli, J. F., et al. (2012) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2012.04.021 · Cited by 489
Self-citationWorgall, S., Sondhi, D., Hackett, N. R., Kosofsky, B., Kekatpure, M. V., Neyzi, N., Dyke, J. P., Ballon, D., Heier, L., Greenwald, B. M., et al. (2008) · Human Gene Therapy · doi:10.1089/hum.2008.022 · Cited by 402
Transcription factor EB (TFEB) is a new therapeutic target for Pompe disease
Spampanato, C., Feeney, E., Li, L., Cardone, M., Lim, J., Annunziata, F., Zare, H., Polishchuk, R., Puertollano, R., Parenti, G., et al. (2013) · EMBO Molecular Medicine · doi:10.1002/emmm.201202176 · Cited by 341
NCL diseases - clinical perspectives
Schulz, A., Kohlschütter, A., Mink, J., Simonati, A., & Williams, R. (2013) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2013.04.008 · Cited by 246
Self-citationLysosome biogenesis in health and disease
Bajaj, L., Lotfi, P., Pal, R., Ronza, A. D., Sharma, J., & Sardiello, M. (2019) · Journal of Neurochemistry · doi:10.1111/jnc.14564 · Cited by 153
Nickel, M., Simonati, A., Jacoby, D., Lezius, S., Kilian, D., Van de Graaf, B., Pagovich, O. E., Kosofsky, B., Yohay, K., Downs, M., et al. (2018) · The Lancet Child & Adolescent Health · doi:10.1016/s2352-4642(18)30179-2 · Cited by 148
Self-citationRadke, J., Stenzel, W., & Goebel, H. H. (2015) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2015.05.007 · Cited by 122
Cerliponase Alfa: First Global Approval
Markham, A. (2017) · Drugs · doi:10.1007/s40265-017-0771-8 · Cited by 120
Cited by
Homozygous GRN mutations: new phenotypes and new insights into pathological and molecular mechanisms
Huin, V., Barbier, M., Bottani, A., Lobrinus, J. A., Clot, F., Lamari, F., Chat, L., Rucheton, B., Fluchère, F., Auvin, S., et al. (2020) · Brain · doi:10.1093/brain/awz377 · Cited by 96
Pathomechanisms in the neuronal ceroid lipofuscinoses
Nelvagal, H. R., Lange, J., Takahashi, K., Tarczyluk-Wells, M. A., & Cooper, J. D. (2020) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2019.165570 · Cited by 80
Self-citationSondhi, D., Kaminsky, S. M., Hackett, N. R., Pagovich, O. E., Rosenberg, J. B., De, B. P., Chen, A., Van de Graaf, B., Mezey, J. G., Mammen, G. W., et al. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.abb5413 · Cited by 72
Moving towards a new era of genomics in the neuronal ceroid lipofuscinoses
Butz, E. S., Chandrachud, U., Mole, S. E., & Cotman, S. L. (2020) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2019.165571 · Cited by 62
Self-citationSyndromic retinitis pigmentosa.
Karuntu, J. S., Almushattat, H., Nguyen, X.-T.-A., Plomp, A. S., Wanders, R. J. A., Hoyng, C. B., van Schooneveld, M. J., Schalij-Delfos, N. E., Brands, M. M., Leroy, B. P., et al. (2025) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2024.101324 · Cited by 39
Metadata
- Authors
- Mole, S. E., Anderson, G., Band, H. A., Berkovic, S. F., Cooper, J. D., Kleine Holthaus, S.-M., McKay, T. R., Medina, D. L., Rahim, A. A., Schulz, A., & Smith, A. J.
- Venue
- The Lancet Neurology
- Publisher
- Elsevier BV
- Published
- 2019-01
- Volume
- 18
- Issue
- 1
- Pages
- 107-116
- ISSN
- 1474-4422 (ISSN-L)
- OpenAlex
- W2900909297
- Cited by
- 206
- References
- 9
- FWCI
- 10.69
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Clinical challenges and future therapeutic approaches for neuronal ceroid lipofuscinosis. https://app.cochat.ai/papers/10.1016/s1474-4422(18)30368-5
- The paper
- Mole, S. E., Anderson, G., Band, H. A., Berkovic, S. F., Cooper, J. D., Kleine Holthaus, S.-M., McKay, T. R., Medina, D. L., Rahim, A. A., Schulz, A., & Smith, A. J. (2019). Clinical challenges and future therapeutic approaches for neuronal ceroid lipofuscinosis. The Lancet Neurology. https://doi.org/10.1016/s1474-4422(18)30368-5
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.